StartIPN • EPA
add
Ipsen
Seneste lukkekurs
109,50 €
Dagsinterval
108,80 € - 109,60 €
Årsinterval
99,70 € - 126,70 €
Markedsværdi
9,10 mia. EUR
Gns. volumen
60,51 t
P/E-værdi
13,41
Udbytteprocent
1,10 %
Primær børs
EPA
I nyhederne
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(EUR) | jun. 2024info | År til år-ændring |
---|---|---|
Indtægt | 875,90 mio. | 7,93 % |
Driftsudgifter | 557,05 mio. | 8,31 % |
Nettoindtægt | 116,00 mio. | 18,85 % |
Overskudsgrad | 13,24 | 10,06 % |
Earnings per share | — | — |
EBITDA | 240,85 mio. | 0,31 % |
Effektiv afgiftssats | 16,30 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(EUR) | jun. 2024info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 485,40 mio. | 17,42 % |
Samlede aktiver | 6,55 mia. | 7,50 % |
Samlede passiver | 2,50 mia. | -6,93 % |
Samlet egenkapital | 4,05 mia. | — |
Shares outstanding | 82,86 mio. | — |
Kurs/indre værdi | 2,24 | — |
Afkast af aktiver | 6,13 % | — |
Afkast af kapital | 8,85 % | — |
Pengestrøm
Nettoændring i likviditet
(EUR) | jun. 2024info | År til år-ændring |
---|---|---|
Nettoindtægt | 116,00 mio. | 18,85 % |
Pengestrøm fra drift | 233,00 mio. | 8,52 % |
Pengestrøm fra investering | -99,55 mio. | 79,81 % |
Pengestrøm fra finansiering | -159,10 mio. | -51,45 % |
Nettoændring i likviditet | -26,00 mio. | 93,10 % |
Fri pengestrøm | 15,01 mio. | -89,78 % |
Om
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
Administrerende direktør
Grundlagt
1929
Website
Ansatte
5.325